Advanced Biosciences Research Report issue

For profit Phase 3
Founded: United Kingdom (2010)
Status: Acquired by bioRASI, LLC (2014)

Organization Overview

First Clinical Trial
2012
NCT01550614
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

alferminogene tadenovec (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina Pectoris (Phase 3)

Angina, Stable (Phase 3)

Coronary Artery Disease (Phase 3)

Myocardial Ischemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1